Last-Chance drug access for rare blood cancer patients
NCT ID NCT05269771
Summary
This program provided access to the drug ruxolitinib for polycythemia vera patients who couldn't tolerate standard treatments. It was designed for compassionate use when other options had failed. The program is no longer accepting new patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Orange, New South Wales, 2800, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Calgary, Alberta, T2N 2T9, Canada
-
Novartis Investigative Site
Tehran, 11367, Iran
-
Novartis Investigative Site
Kfar Saba, Israel, 44281, Israel
-
Novartis Investigative Site
Kfar Saba, 44281, Israel
-
Novartis Investigative Site
Rehovot, 7610001, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Tel Giborim Holon, 58100, Israel
-
Novartis Investigative Site
Groningen, 9700RB, Netherlands
-
Novartis Investigative Site
Gdansk, 80-214, Poland
-
Novartis Investigative Site
Katowice, 40-027, Poland
-
Novartis Investigative Site
Krakow, 31-501, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Warsaw, 04-141, Poland
-
Novartis Investigative Site
Wałbrzych, 58-309, Poland
-
Novartis Investigative Site
Wroclaw, 50-367, Poland
-
Novartis Investigative Site
Hereford, HR1 2ER, United Kingdom
-
Novartis Investigative Site
Kent, CT9 4AN, United Kingdom
-
Novartis Investigative Site
London, NW3 2PF, United Kingdom
-
Novartis Investigative Site
London, SE5 8AD, United Kingdom
-
Novartis Investigative Site
London, WC1E 6HX, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LJ, United Kingdom
-
Novartis Investigative Site
Poole, BH15 2JB, United Kingdom
-
Novartis Investigative Site
Salisbury, SP2 8BJ, United Kingdom
Conditions
Explore the condition pages connected to this study.